Yingying Xu

4PUBLICATIONS
4CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologySolid tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 25, 2025
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial.

Qiang Zhang, Mozhi Wang, Yumeng Li

|Jul 02, 2024
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis.

Shirong Tan, Xiangyu Sun, Haoran Dong

|Jan 11, 2024
The Role of Breast Cancer Cells in Bone Metastasis: Suitable Seeds for Nourishing Soil.

Yiou Wang, Yue Hu, Mozhi Wang

|Oct 16, 2023
KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer.

Litong Yao, Qian Hao, Mozhi Wang

Pageof 1

Frequent Collaborators

1 joint publications

Keda Yu

1 joint publications

Yizhou Jiang

1 joint publications

Xiang Zhou

1 joint publications

Bo Zhu